Dallas Diabetes and Endocrine Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2006
NCT00345410
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Dallas Diabetes and Endocrine Center 7777 Forest Lane, C-618 Dallas TX 75230 USA

Active Ingredients

Drugs in Phase 2 Trials (2)

ave-1625 (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Dyslipidemias (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2